Google, IBM & Meta Certificates — All 10,000+ Courses at 40% Off
One annual plan covers every course and certificate on Coursera. 40% off for a limited time.
Get Full Access
Learn about the latest prostate cancer clinical updates from ASCO 2025 in this 29-minute medical education video. Discover key findings from three major studies: AMPLITUDE showing how Niraparib combined with Abiraterone and ADT improves radiographic progression-free survival in HRR-mutated metastatic castration-sensitive prostate cancer, ARANOTE demonstrating that Darolutamide plus ADT is the first and only androgen receptor pathway inhibitor to improve health-related quality of life in mCSPC, and IRONMAN providing real-world evidence that PSA levels at 6 and 12 months serve as prognostic indicators when using ADT plus ARPI treatment combinations.
